Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 20/20 | 0.48 |
| ▸ | CBL | P22681 | 18/20 | 0.47 |
| ▸ | CBLC | Q9ULV8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25413016 | 1.00 | CBLB (0.48) | CBLBCBLCBLC | |
| SCHEMBL30184959 | 0.92 | CBLB (0.52) | CBLBCBLCBLC | |
| SCHEMBL30184958 | 0.92 | CBLB (0.52) | CBLBCBLCBLC | |
| SCHEMBL31251387 | 0.89 | CBLB (0.46) | CBLBCBLCBLC | |
| SCHEMBL31015521 | 0.89 | CBLB (0.50) | CBLBCBLCBLC | |
| SCHEMBL30800289 | 0.88 | CBLB (0.43) | CBLBCBLCBLC | |
| SCHEMBL25180071 | 0.88 | CBLB (0.41) | CBLBCBLCBLC | |
| SCHEMBL25413553 | 0.86 | CBLB (0.44) | CBLBCBL | |
| SCHEMBL31458873 | 0.86 | CBLB (0.44) | CBLBCBLCBLC | |
| SCHEMBL31459418 | 0.86 | CBLB (0.44) | CBLBCBL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2026-01-08 | — | — | US | disclosed |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| EP-4558504-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025067468-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025067227-A1 | PREPARATION METHOD FOR CBL-B REGULATOR, AND USE | 浙江华海药业股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119630662-A | CBL-B inhibitors and methods of use thereof | 英矽智能科技知识产权有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-4490152-A1 | ACTIVATORS OF EFFECTOR T CELLS | Orum Therapeutics Inc. (KR) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024255762-A1 | CBL-B INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2024-12-19 | — | — | WO | disclosed |
| WO-2024245264-A1 | CBL-B INHIBITOR AND USE THEREOF | 海南先声再明医药股份有限公司 | 2024-12-05 | — | — | WO | disclosed |
| WO-2024153246-A1 | SUBSTITUTED TRICYCLIC COMPOUND AND USE THEREOF | 海南先声再明医药股份有限公司 | 2024-07-25 | — | — | WO | disclosed |
| WO-2024017201-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023170608-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023170608-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023151642-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151641-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151640-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | CBL, CBLC, CBLB | CBLB 3/4885CBL 1/4885CBLC 2/4885 |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | CBLB 1/4885CBL 2/4885CBLC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.